Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

NTRK Fusion in Lung Cancer and the Role of TRK Inhibitors
  • CME
  • MOC

Credits Available
Physicians: maximum of 1.5 AMA PRA Category 1 Credits
ABIM MOC: maximum of 1.5 Medical Knowledge MOC point(s)
Released: January 28, 2021 Expiration: January 27, 2022
Start Activity
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Bayer HealthCare Pharmaceuticals Inc.
Turning Point Therapeutics Inc.
Todd M. Bauer, MD
Alexander Drilon, MD

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Describe the biology of and rationale for targeting NSCLC harboring NTRK fusions 

  • Identify patients with NSCLC who should be tested for NTRK fusions with established and emerging biomarker assays

  • Describe the research data supporting the use of TRK inhibition in NTRK fusion–positive NSCLC 
  • Formulate strategies for using TRK inhibitors in the management of patients with NSCLC
  • Develop treatment strategies for patients with NSCLC who develop acquired resistance to first-generation TRK inhibitor therapy
  • Refer patients with NSCLC to ongoing late-phase clinical trials of TRK inhibitors

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Faculty

Todd M. Bauer, MD

Associate Director, Drug Development
Sarah Cannon Research Institute
Tennessee Oncology, PLLC
Nashville, Tennessee

Todd M. Bauer, MD, has disclosed that he has received funds for research support paid to his institution from AbbVie, Aileron, Amgen, Armo, Astellas, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Calithera, Clovis Oncology, Daiichi Sankyo, Deciphera, Five Prime Therapeutics, Foundation Medicine, Genentech/Roche, GlaxoSmithKline, Immunocore, ImmunoGen, Incyte, Ignyta, Jacobio, Janssen, Leap, Lilly, Loxo, Karyopharm, Kolltan, MabVax, MedImmune, Medpacto, Merck, Mirati, Merrimack, Millennium, Moderna, Novartis, Onyx, Peleton, Pfizer, Phosplatin Therapeutics, Principa Biopharma, Roche, Sanofi, Stemline, Takeda, and Top Alliance BioScience; has received consulting fees paid to his institution from Ignyta, Moderna, and Pfizer; has received consulting fees from AstraZeneca, Bayer, Blueprint Medicines, Exelixis, Foundation Medicine, Guardant, Loxo, and Pfizer; and has served on the speaker bureau for Bayer, Bristol-Myers Squibb, and Lilly.
Alexander Drilon, MD

Chief, Early Drug Development
Attending, Thoracic
Memorial Sloan Kettering Cancer Center
New York, New York

Alexander Drilon, MD, has disclosed that he has received consulting fees from 14ner/Elevation Oncology, AbbVie, ArcherDX, AstraZeneca, BeiGene, BergenBio, Blueprint Medicines, EMD Serono, Exelixis, Helsinn, Hengrui, Ignyta/Genentech/Roche, Loxo/Bayer/Lilly, Melendi, Monopteros, MORE Health, Novartis, Pfizer, Remedica, Takeda/Ariad/Millennium, TP Therapeutics, Tyra Biosciences, and Verastem; funds for research support from Foundation Medicine; funds for research support paid to his institution from Exelixis, GlaxoSmithKline, Pfizer, PharmaMar, Taiho, and Teva; and royalties from Wolters Kluwer.

Staff

Terrence Fagan

Associate Scientific Director

Terrence Fagan has no relevant conflicts of interest to report.
Gordon Kelley

Senior Clinical Editor

Gordon Kelley has no relevant conflicts of interest to report.
Timothy A. Quill, PhD

Associate Director, Scientific Services

Timothy Quill, PhD, has no relevant conflicts of interest to report.
Krista Marcello

Associate Director, Educational Strategy

Krista Marcello, PhD, has no relevant conflicts of interest to report.
Kevin Obholz, PhD

Senior Director, Educational Strategy

Kevin Obholz, PhD, has no relevant conflicts of interest to report.
Tanja Link, PhD

Editorial Contributor

Tanja Link, PhD, has no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for physicians and other healthcare providers who care for patients with lung cancer.

Goal

The goal of this activity is to improve the knowledge, confidence, and competence of oncology specialists and other clinicians to screen patients with lung cancer for NTRK fusions and integrate TRK inhibitors into treatment of their patients with lung cancer.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine Maintenance of Certification

Successful completion of this activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.5 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from January 28, 2021, through January 27, 2022:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

NTRK Fusion in Lung Cancer and the Role of TRK Inhibitors
  • CME
  • MOC

Loading...
Watch this on-demand Webcast capturing a live CCO Webinar featuring expert presentations on evolving awareness of NTRK fusions in lung cancer and the role of TRK inhibitors.
Todd M. Bauer, MD
Alexander Drilon, MD
Physicians: maximum of 1.5 AMA PRA Category 1 Credits
ABIM MOC: maximum of 1.5 Medical Knowledge MOC point(s)
Released: January 28, 2021 Expiration: January 27, 2022

Related Content

Phase I/II trial of mobocertinib for EGFR ex20ins+ advanced NSCLC in cohort of patients with disease progression after initial disease control on EGFR TKI therapy, from WCLC 2021 by Clinical Care Options (CCO)

Released: September 23, 2021

Initial analysis of amivantamab in patients with METex14+ metastatic or unresectable NSCLC from phase I CHRYSALIS trial, from WCLC 2021 as reported by Clinical Care Options (CCO)

Released: September 23, 2021

Downloadable summary slideset from a live CCO Webinar on immunotherapy for the treatment of patients across the spectrum of NSCLC

Julie Brahmer, MD, MSc person default Jarushka Naidoo, MB BCH BAO, MHS Released: September 23, 2021

3-year update of CASPIAN showed sustained survival benefit of adding durvalumab to platinum-etoposide for first-line treatment in extensive-stage SCLC, presented at ESMO 2021 and reported by Clinical Care Options (CCO)

person default Eva Ciruelos, MD, PhD Karim Fizazi, MD, PhD Eric Van Cutsem, MD, PhD person default Vamsidhar Velcheti, MD Released: September 23, 2021
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Bayer HealthCare Pharmaceuticals Inc.
Turning Point Therapeutics Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue